Get started
Author

Giuseppina Loglisci

Observed names: G Loglisci, G. Loglisci
Institution: Ospedale Vito Fazzi
OpenAlex ID: A5035666231
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience
2011 · C. Girmenia, A. M. Frustaci, et al. · Haematologica · 67
PDF
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols
2011 · Massimo Breccia, Luca Mazzarella, et al. · Blood · 66
“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia
2010 · Roberto Latagliata, Massimo Breccia, et al. · Leukemia Research · 55
FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis
2013 · M. Breccia, G. Loglisci, et al. · Haematologica · 54
PDF
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients
2010 · Massimo Breccia, Vincenzo Federico, et al. · Leukemia Research · 39
Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population
2012 · Massimo Breccia, Paola Finsinger, et al. · Annals of Hematology · 32
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index
2012 · Massimo Breccia, Giuseppina Loglisci, et al. · Leukemia Research · 29
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib
2013 · Massimo Breccia, Giuseppina Loglisci, et al. · Cancer Letters · 25
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report
2021 · Massimo Breccia, Elisabetta Abruzzese, et al. · British Journal of Haematology · 24
PDF
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
2012 · M. Breccia, A. Salaroli, et al. · Haematologica · 23
PDF
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
2012 · Massimo Breccia, Giuseppina Loglisci, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line
2012 · Massimo Breccia, Paola Finsinger, et al. · Leukemia Research · 22
Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase
2011 · Massimo Breccia, Corrado Girmenia, et al. · Mediterranean Journal of Hematology and Infectious Diseases · 22
PDF
Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response
2010 · Massimo Breccia, Giuseppina Loglisci, et al. · Acta Haematologica · 22
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes
2012 · Adriano Salaroli, Giuseppina Loglisci, et al. · Annals of Hematology · 19
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
2012 · Massimo Breccia, Giuseppina Loglisci, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 18
Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients
2010 · Massimo Breccia, Roberto Latagliata, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 17
Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine
2012 · Massimo Breccia, Adriano Salaroli, et al. · Annals of Hematology · 15
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes
2011 · M. Breccia, V. Federico, et al. · Haematologica · 15
PDF
Suboptimal response to imatinib according to 2006–2009 European LeukaemiaNet criteria: a ‘grey zone’ at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention
2010 · Massimo Breccia, Sonia M. Orlandi, et al. · British Journal of Haematology · 10
PDF
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
2023 · Mario Tiribelli, Roberto Latagliata, et al. · Cancer · 8
PDF
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia
2012 · Massimo Breccia, Alessandra Serrao, et al. · British Journal of Haematology · 7
An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy
2011 · Valeria Santini, Alessandro Sanna, et al. · Blood · 7
Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience
2012 · Massimo Breccia, Paola Finsinger, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome
2011 · Massimo Breccia, Laura Cannella, et al. · Journal of Clinical Oncology · 6
Works count: 85
Citation count: 723
H-index: 17
I10-index: 20
Year
Topic
Type